http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2375094-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48 |
| filingDate | 2007-01-10^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-02-24^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2aeae1433467f3e08ac19e1d7497a1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3a2316827039d6ee2f6876063e8979d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d7e706a6cf7452432c2c6ab9a65e8ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_368926448f30bfc3cf8508121efd62c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a02191d4333ba50fc2bfff6ed82c2aa5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12c80f191acf4b224a82e26f2a497d33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_582d17901d4d6868d2215b78d7819643 |
| publicationDate | 2012-02-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2375094-T3 |
| titleOfInvention | UROTENSIN II RECEIVER ANTAGONISTS II. |
| abstract | A compound of Formula (I); Formula (I) in which: when A is present, then G is selected from hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 3-14 cycloalkyl or a C-([R 1) (R 11)] - LD moiety: the C1-8 alkyl being optionally substituted with one, two or three fluorine substituents, and the C3-14 cycloalkyl being optionally substituted with one, two or three C1-3 alkyl substituents; or, when A is absent and R2 is other than benzyloxymethyl, then G is C1-8 alkoxy or heterocyclyloxy, the C1-8 alkoxy being substituted with one of amino, (C1-8 alkyl) amino, di (C1-8 alkyl) amino, (benzyl) amino or [(benzyl) (C1-4 alkyl)] amino, and the heterocyclyloxy optionally substituted in the heterocyclyl with one, two or three C1-3 alkyl substituents; R1 is selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, and C2-8 alkynyl; R11 is selected from the group consisting of hydrogen, C1-8 alkyl and cyclopropyl; L is absent or is C1-4 alkylene; D is aryl (other than naphthalen-2-yl), C3-14 cycloalkyl, C5-14 cycloalkenyl, heterocyclyl or heteroaryl, the aryl and heteroaryl being optionally substituted with one, two, three or four substituents independently selected from the group that consists of C1-3 alkyl, C1-3 alkoxy, C2-8 alkenyl, C2-3 alkenyloxy, hydroxy, C1-3 alkylthio, fluorine, chlorine, cyano, C1-3 alkylcarbonyl, (C1-3 alkylcarbonyl) amino, (alkyl C1-3) amino, di (C1-3 alkyl) amino and C3-14 cycloalkyl, the C3-14 cycloalkyl being optionally substituted with one, two, three or four C1-3 alkyl substituents, with the proviso that D is different of 2-hydroxy 5-chloro-phenyl, 3-methoxy-phenyl, 4-ethyl-phenyl, 6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl-methyl, cyclohex-3-enyl, 2,6-dichloro-phenyl and 2-chloro-4-fluoro-phenyl; A is an optionally present biradical selected from the group consisting of a-1, a-2 optionally unsaturated, a-3, a-4, a-5 optionally unsaturated and a-6, in which the lower part of A it is attached, with respect to the nitrogen atom of Formula (I), to position 3 or 4 in the benzene ring part of Formula (I); where a-1, a-2, a-3, a-4 and a-5 are optionally substituted with one to two C1-4 alkyl substituents; with the proviso that A is other than cis- (1,2) -cyclohexyldiamino; R4 is hydrogen or C1-8 alkyl; L2 is absent or is -C (R2) (R5) - (CR6R7) r-, where r is 0, 1 or 2; and wherein R5, R6, and R7 are independently hydrogen or C1-3 alkyl; with the proviso that L2 is different from -CH (R-carboxymethyl) -; R2 is selected from the group consisting of a heteroaryl that is not condensed with another ring, phenyl and C1-6 alkyl, the phenyl being optionally substituted with (R200-C1-6 alkyl) amino, or [(hydroxysulfonyl) (Ra) ] amino, and the C1-8 alkyl being optionally substituted with carboxy, hydroxy, R200, NRaRb, C1-6 alkoxy, R200-C1-6 alkoxy, R200-oxy, aminocarbonyl, C1-6 carboxy-alkoxy, aminocarbonyl-C1 alkoxy -6, (C1-8 alkyl) aminocarbonyl, di (C1-8 alkyl) aminocarbonyl, [(R200-C1-6 alkyl) (Ra)] amino, (C1-6 alkylcarbonyl) amino, (trihalo-C1-4 alkylcarbonyl) ) amino, (R200- C1-6 alkylcarbonyl) amino, (C1-6 alkoxycarbonyl) amino, (R200-C1-6 alkoxycarbonyl) amino, (C1-6 alkoxy-C1-9 alkylcarbonyl) amino, (R200-carbonyl) amino , (amino- C 1-6 alkylcarbonyl) amino, [(C 1-6 alkyl) amino C 1-6 alkylcarbonyl] amino, [di (C 1-6 alkyl) aminoC 1-8 alkylcarbonyl] amino, (C 1-6 alkylcarbonyl) acetonitrile-carbonyl) 5 amino, ureido, thioureido, acetamidino, guanidino, {[(R200) (Ra)] aminocarbonyl- (Rc)} amino, [(R200-oxycarbonyl) (Ra)] amino, [(R200) (Ra)] aminocarbonyloxy, aminosulfonyl, C1-6 alkylsulfonyl, (C1-6 alkylsulfonyl) amino, (R200-C1-6 alkylsulfonyl) amino, (R200- C2-6 alkenylsulfonyl) amino, (C1-6 alkylsulfonyl-C1-8 alkylsulfonyl) amino, R200-sulfonyloxy, aminosulfonyloxy, (C1-6 alkyl) aminosulfonyloxy, di (C1-6 alkyl) aminosulfonyloxy, aminosulfonylamino, (C1-6 alkyl ) aminosulfonylamino, [di (C1-6 alkyl) aminosulfonyl] amino, [(hydroxysulfonyl) (Ra)] amino, [(R200-oxysulfonyl) (Ra)] amino, [(R200-sulfonyl) (Ra)] amino, [ (R200) (Ra)] aminosulfonyloxy, or ({[(R200) (Ra)] aminosulfonyl} (Rc)) amino; Ra and Rc are independently selected from the group consisting of hydrogen and C1-6 alkyl; and Rb is hydrogen, C1-6 alkyl, C6-10 aryl, heteroaryl, C3-8 cycloalkyl or heterocyclyl; R200 is C6-10 aryl, heteroaryl, C3-8 cycloalkyl, or heterocyclyl, each optionally substituted with one, two or three substituents independently selected from the group consisting of C1-4 alkyl, trihalo-C1-4 alkyl, C1 alkoxy -4, trihalo-C1-4 alkoxy, C1-6 alkylcarbonyl, C1-9 alkoxycarbonyl, (C1-6 alkylcarbonyl) amino, C1-6 alkylsulfonyl, hydroxysulfonyl, aminosulfonyl, chlorine, fluorine, bromine, aryl, heteroaryl, aryl-alkyl C1-6, arylsulfonyl and heteroaryl sulfonyl, the heterocyclyl being optionally substituted with one, two or three oxo substituents; B is C6-10 aryl, tetralinyl, indanyl or a heteroaryl selected from the group consisting of pyridin-2-yl, pyridin-4-yl, pyrazol-4-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, imidazol-1-yl, thien-2-yl, isoquinolinyl, indolyl, quinolinyl and thiazol-5-yl, B being optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl C1-4, C1-4 alkoxy, fluorinated C (C1-4) alkoxy, halogen, cyano, hydroxy, aminocarbonyl, alkylaminocarbonyl (C1-4), dialkylaminocarbonyl (C1-4), aminosulfonyl, alkylaminosulfonyl (C1-4), dialkylaminosulfonyl (C1-4), hydroxysulfonyl, aminosulfonylamino, alkylaminosulfonylamino (C1-4), dialkylaminosulfonylamino (C1-4), aminosulfonyloxy, (C1-4) alkylaminosulfonyloxy and di (C1-4) alkylaminosulfonyloxy, with the proviso that when B is selected between the group consisting of C6-10 aryl, tetralinyl, indanyl, thien-2-yl, and indolyl, then B is independently and substituted with two to three substituents selected from the group consisting of C1-3 alkoxy and hydroxy, with the proviso that when B is phenyl substituted at positions 3,4-, 3,5- or 4,5 with a C1-3 alkoxy substituent unbranched in each position, then the phenyl may be optionally further substituted in a remaining open 3, 4 or 5 position with an additional C1-3 alkoxy or hydroxy substituent, and with the proviso that B is different from 3-hydroxy-4-methoxy-phenyl and 3- (n-propyloxy) -4-methoxy-phenyl; E is hydrogen, halogen, C1-3 alkoxy, C2-5-RE alkyl, or -CH = CH-C0-3-RE alkyl; RE being selected from the group consisting of carboxy, amino, (C1-6 alkyl) amino, di (C1-6 alkyl) amino, aminocarbonyl, (C1-6 alkyl) aminocarbonyl, di (C1-6 alkyl) aminocarbonyl, (alkyl C1-6) carbonylamino, C1-6 alkoxycarbonylamino, aminocarbonylalkoxy (C1-6), ureido, thioureido, aminosulfonyl, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, aminosulfonyloxy, (C1-6 alkyl) aminosulfonyloxy, di (C1-6 alkyl ) aminosulfonyloxy, aminosulfonylamino, (C1-6 alkyl) aminosulfonylamino, di (C1-6 alkyl) aminosulfonylamino, (R200) (Ra) aminocarbonyl- (Rc) amino, R200carbonylamino, R200oxycarbonyl- (Ra) amino, (R200) (Ra) aminocarbonyloxy, R200oxisulfonyl- (Ra) amino, R200sulfonyl- (Ra) amino, (R200) (Ra) aminosulfonyloxy and (R200) (Ra) aminosulfonyl- (Rc) amino; X and Y are independently O or S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof. |
| priorityDate | 2006-01-10^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 955 of 955.